Myomo, Inc. announced on May 4, 2026 that its MyoPro powered arm brace will now be available through Ottobock Care clinics across the United States, extending the device’s reach to a broader network of orthotic and prosthetic providers.
The partnership is part of Myomo’s strategy to diversify sales channels beyond direct‑to‑patient advertising and Medicare billing. By leveraging Ottobock’s established O&P provider network, Myomo expects to reduce customer acquisition costs and accelerate market penetration. The company’s goal of achieving a quarterly revenue breakeven of $16‑$17 million is supported by this expansion, which is expected to lift unit sales and help close the gap between current revenue and breakeven targets.
Myomo’s recent financials provide context for the partnership’s impact. In Q4 2025 the company generated $11.4 million in revenue, up from $10.1 million in Q3 2025, and a full‑year 2025 revenue of $40.9 million, a 26% increase over 2024. The new distribution channel is projected to add a significant volume of units, thereby improving revenue momentum and supporting the company’s path to profitability.
CEO Paul R. Gudonis said, “We are pleased to be working with Ottobock Care’s clinical specialists and have already supported their efforts by training their clinicians in regions across the country.” Ottobock’s Head of Patient Services, Kevin Heidenreich, added, “The MyoPro fits well into our strategy to position our O&P clinics as leaders in providing enhanced neuro‑robotic solutions to our patient population.”
The partnership comes at a time when reimbursement from Medicare and private insurers is expanding for the MyoPro, and Myomo is actively working to increase in‑network coverage. While the company faces ongoing headwinds such as competitive pressure and reimbursement uncertainty, the expanded access through Ottobock Care is expected to strengthen its market position and accelerate revenue growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.